Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus

• Main Authors: Swati Singh, Leah J. Homad, Nicholas R. Akins, Claire M. Stoffers, Stefan Lackhar, Harman Malhi, Yu-Hsin Wan, David J. Rawlings, Andrew T. McGuire
• Format: Article
• Language: English
• Published: Elsevier 2020-06-01
• Series: Cell Reports Medicine
• Online Access: http://www.sciencedirect.com/science/article/pii/S2666379120300458

Summary: Epstein-Barr virus (EBV) is a cancer-associated pathogen for which there is no vaccine. Successful anti-viral vaccines elicit antibodies that neutralize infectivity; however, it is unknown whether neutralizing antibodies prevent EBV acquisition. Here we assessed whether passively delivered AMMO1, a monoclonal antibody that neutralizes EBV in a cell-type-independent manner, could protect against experimental EBV challenge in two animal infection models. When present prior to a high-dose intravenous EBV challenge, AMMO1 prevented viremia and reduced viral loads to nearly undetectable levels in humanized mice. AMMO1 conferred sterilizing immunity to three of four macaques challenged orally with rhesus lymphocryptovirus, the EBV ortholog that infects rhesus macaques. The infected macaque had lower plasma neutralizing activity than the protected animals. These results indicate that a vaccine capable of eliciting adequate titers of neutralizing antibodies targeting the AMMO1 epitope may protect against EBV acquisition and are therefore highly relevant to the design of an effective EBV vaccine.